This newest twist inside the Lykos Therapeutics saga threatens A significant overhaul of the corporation’s tactic and course, with Musk ally and billionaire investor Antonio Gracias appearing to want to choose the corporate again toward its nonprofit drug development roots and a more Doblinite philosophy.“This may have occurred in the past, whe